Literature DB >> 35332815

Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).

Marcello Moccia1, Giuseppina Affinito2, Bruno Ronga3, Roberta Giordana4, Maria Grazia Fumo5, Roberta Lanzillo1, Maria Petracca6, Antonio Carotenuto1, Maria Triassi2, Vincenzo Brescia Morra1, Raffaele Palladino7.   

Abstract

BACKGROUND: Emergency hospital admissions are common in multiple sclerosis (MS), and can highlight unmet medical needs.
OBJECTIVES: To evaluate burden, predictors and outcomes of MS emergency admissions.
METHODS: This is a population-based study, conducted in the Campania Region (South Italy) from 2015 to 2019, using hospital discharge records, drug prescriptions and outpatients. The risk of emergency hospital admissions and the likelihood of worse outcomes were evaluated using the Cox regression and multinomial logistic regression models, respectively, in relation to age, sex, disease-modifying treatments (DMTs), comorbidities and adherence.
RESULTS: We recorded 1225 emergency admissions for 1001 patients (out of 5765 prevalent MS patients), overall costing 4,143,764.67 EUR. The risk of emergency admissions increased with age (hazard ratio (HR) = 1.02; 95% confidence interval (CI) = 1.01, 1.03; p < 0.01) and comorbidities (HR = 1.62; p < 0.01), and decreased in patients using DMTs (interferon beta/peg-interferon beta/glatiramer acetate HR = 0.19; p < 0.01; teriflunomide/dimethyl-fumarate/fingolimod HR = 0.18; p < 0.01, and alemtuzumab/cladribine/natalizumab/ocrelizumab HR = 0.21; p < 0.01), and with higher adherence (HR = 0.18; 95% CI = 0.13, 0.26; p < 0.01). Following emergency admission, older age was associated with probability of death (n = 63) (odds ratio (OR) = 1.06; p < 0.01) and discharge to long-term facility (n = 65) (OR = 1.03; p = 0.01).
CONCLUSION: With 17% people with MS requiring emergency medical care over 5 years, improved management of DMTs and comorbidities could potentially reduce their medical, social and financial burden.

Entities:  

Keywords:  Multiple sclerosis; adherence; cost; death; emergency; treatment

Mesh:

Substances:

Year:  2022        PMID: 35332815     DOI: 10.1177/13524585221074010

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

1.  Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.

Authors:  Alise Carlson; Marisa P McGinley
Journal:  Mult Scler       Date:  2022-03-16       Impact factor: 6.312

2.  Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.

Authors:  Marcello Moccia; Giuseppina Affinito; Giulia Berera; Giuseppina Marrazzo; Raffaele Piscitelli; Antonio Carotenuto; Maria Petracca; Roberta Lanzillo; Maria Triassi; Vincenzo Brescia Morra; Raffaele Palladino
Journal:  J Neurol       Date:  2022-08-11       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.